Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Merrilee Needham

Showing results (101-110 of 113) with videos related to

Pageof 12
Sort By:
Nature Neuroscience|November 25, 2025
Large-scale drug screening in iPSC-derived motor neurons from sporadic ALS patients identifies a potential combinatorial therapyChristopher R Bye, Elizabeth Qian, Katherine Lim, et al.
Clinical and Experimental Rheumatology|February 28, 2025
Optimism in inclusion body myositis: a double-blind randomised controlled phase III trial investigating the effect of sirolimus on disease progression in patients with IBM as measured by the IBM Functional Rating ScaleUmesh A Badrising, Robert Henderson, Stephen Reddel, et al.
NPJ Genomic Medicine|March 7, 2020
Significant out-of-sample classification from methylation profile scoring for amyotrophic lateral sclerosisMarta F Nabais, Tian Lin, Beben Benyamin, et al.
BMJ Open|June 18, 2026
Strategic Amyotrophic Lateral Sclerosis Australia-Systems Genomics Consortium (SALSA-SGC): cohort profileAnjali K Henders, Laura Ziser, Fleur C Garton, et al.
Plos One|May 25, 2013
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosisTomas Kalincik, Timothy Spelman, Maria Trojano, et al.
The Lancet. Neurology|August 10, 2019
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trialMichael G Hanna, Umesh A Badrising, Olivier Benveniste, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 24, 2020
A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of <i>Reldesemtiv</i> In Patients With ALSJeremy M Shefner, Jinsy A Andrews, Angela Genge, et al.
Neurology|February 18, 2021
Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENTAnthony A Amato, Michael G Hanna, Pedro M Machado, et al.
Genome Biology|March 27, 2021
Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disordersMarta F Nabais, Simon M Laws, Tian Lin, et al.
Science Translational Medicine|February 23, 2022
Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALSPaul J Hop, Ramona A J Zwamborn, Eilis Hannon, et al.
Pageof 12

Showing results (101-110 of 113) with videos related to

Sort By:
Pageof 12
Nature Neuroscience|November 25, 2025
Large-scale drug screening in iPSC-derived motor neurons from sporadic ALS patients identifies a potential combinatorial therapyChristopher R Bye, Elizabeth Qian, Katherine Lim, et al.
Clinical and Experimental Rheumatology|February 28, 2025
Optimism in inclusion body myositis: a double-blind randomised controlled phase III trial investigating the effect of sirolimus on disease progression in patients with IBM as measured by the IBM Functional Rating ScaleUmesh A Badrising, Robert Henderson, Stephen Reddel, et al.
NPJ Genomic Medicine|March 7, 2020
Significant out-of-sample classification from methylation profile scoring for amyotrophic lateral sclerosisMarta F Nabais, Tian Lin, Beben Benyamin, et al.
BMJ Open|June 18, 2026
Strategic Amyotrophic Lateral Sclerosis Australia-Systems Genomics Consortium (SALSA-SGC): cohort profileAnjali K Henders, Laura Ziser, Fleur C Garton, et al.
Plos One|May 25, 2013
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosisTomas Kalincik, Timothy Spelman, Maria Trojano, et al.
The Lancet. Neurology|August 10, 2019
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trialMichael G Hanna, Umesh A Badrising, Olivier Benveniste, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 24, 2020
A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of <i>Reldesemtiv</i> In Patients With ALSJeremy M Shefner, Jinsy A Andrews, Angela Genge, et al.
Neurology|February 18, 2021
Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENTAnthony A Amato, Michael G Hanna, Pedro M Machado, et al.
Genome Biology|March 27, 2021
Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disordersMarta F Nabais, Simon M Laws, Tian Lin, et al.
Science Translational Medicine|February 23, 2022
Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALSPaul J Hop, Ramona A J Zwamborn, Eilis Hannon, et al.
Pageof 12